Online citations, reference lists, and bibliographies.
← Back to Search

Utility Of Osteopontin And Serum Mesothelin In Malignant Pleural Mesothelioma Diagnosis And Prognosis Assessment

B. Grigoriu, A. Scherpereel, P. Devos, B. Chahine, M. Letourneux, P. Lebailly, M. Grégoire, H. Porte, M. Copin, P. Lassalle
Published 2007 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Purpose: Malignant mesothelioma is a highly aggressive tumor and is often diagnosed too late for a curative treatment. We compared diagnostic and prognostic values of mesothelin and osteopontin in 172 patients suspected of malignant pleural mesothelioma (MPM) and in a control group of 112 asymptomatic asbestos-exposed subjects. Experimental Design: Osteopontin and mesothelin were assayed with commercial ELISA kits in a series of 43 patients with pleural metastases of various carcinomas, 33 patients with benign pleural lesions associated with asbestos exposure, 96 patients with MPMs, and 112 asbestos-exposed healthy subjects. Results were correlated with patient's diagnosis and survival. Results: Serum osteopontin level was higher in MPM patients compared with healthy asbestos-exposed subjects and had a good capability to distinguish between these two populations. However, osteopontin was unable to distinguish between MPM and pleural metastatic carcinoma or benign pleural lesions associated with asbestos exposure. Neither plasma nor pleural fluid osteopontin were more powerful in this respect. Serum mesothelin had a good ability for diagnosing MPM but was unable to identify patients with nonepithelioid mesothelioma subtypes. Survival analysis identified tumor histologic subtype along with serum osteopontin and serum mesothelin as independent prognostic factors in mesothelioma patients. Conclusions: Osteopontin has a lower diagnostic accuracy than mesothelin in patients suspected of MPM. Insufficient specificity limits osteopontin utility as diagnostic marker. Both molecules have a potential value as prognostic markers.
This paper references
10.1016/S1359-6101(03)00055-8
The role of osteopontin in lung disease.
A. O’Regan (2003)
10.1097/00000478-200308000-00001
The Immunohistochemical Diagnosis of Mesothelioma: A Comparative Study of Epithelioid Mesothelioma and Lung Adenocarcinoma
N. Ordóñez (2003)
Prog - nostic significance of osteopontin expression in early - stage non - small - cell lung cancer
L Boldrini (2005)
10.1056/nejmc053112
Asbestos exposure and serum osteopontin.
A. Hiraki (2006)
Rusch VW; from the International Mesothelioma Interest Group. A proposed new international TNM staging system for malignant pleural mesothelioma
(1995)
10.1126/SCIENCE.287.5454.860
Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity.
S. Ashkar (2000)
Cutpoint determination methods in survival analysis using SAS R
MandrekarJN (1999)
10.1158/1078-0432.CCR-05-1580
Association of S100A4 and osteopontin with specific prognostic factors and survival of patients with minimally invasive breast cancer.
S. de Silva Rudland (2006)
10.1378/CHEST.108.4.1122
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)
sociation of S 100 A 4 and osteopontin with specific prognostic factors and survival of patients with minimally invasive breast cancer
S deSilvaRudland (2006)
10.1093/JNCI/94.7.513
Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling.
D. Agrawal (2002)
10.1164/RCCM.200511-1789OC
Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
A. Scherpereel (2006)
Application of mesothelin immunos - taining in tumor diagnosis
N Scholler (2003)
10.1056/NEJMC053112
Asbestos exposure and serum osteopontin.
A. O’Regan (2006)
10.1148/RADIOLOGY.148.3.6878708
A method of comparing the areas under receiver operating characteristic curves derived from the same cases.
J. Hanley (1983)
10.1016/0092-8674(79)90103-X
Transformed mammalian cells secrete specific proteins and phosphoproteins
D. Senger (1979)
10.1056/NEJME058176
Serum osteopontin levels--is it time to screen asbestos-exposed workers for pleural mesothelioma?
M. Cullen (2005)
10.1001/JAMA.287.13.1671
Osteopontin as a potential diagnostic biomarker for ovarian cancer.
J. Kim (2002)
Clin Cancer Res Bogdan-Dragos Grigoriu
Soluble mesothelin-related protein in the diagnosis of malignant pleural mesothelioma
A. Scherpereel (2006)
10.1007/978-1-59259-386-6_11
Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses.
A. Bhattacharjee (2001)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
An application of change - pointmethods in studying the effect of age on survival in breast cancer
C Contal (1983)
10.1046/j.1365-2613.2000.00163.x
Osteopontin: a key cytokine in cell‐mediated and granulomatous inflammation
A. O’Regan (2000)
Osteopontin: possible role in prostate cancer progression.
G. Thalmann (1999)
10.1158/1055-9965.EPI-05-0334
Mesothelin Variant 1 Is Released from Tumor Cells as a Diagnostic Marker
I. Hellstrom (2006)
Osteopon - tin : possible role in prostate cancer progression
GN Thalmann (1999)
Quantifi - cationof osteopontin inhumanplasmawith an ELISA : basal levels in pre - and postmenopausal women
DS Bautista (1996)
10.1158/1078-0432.CCR-06-0472
Megakaryocyte Potentiation Factor Cleaved from Mesothelin Precursor Is a Useful Tumor Marker in the Serum of Patients with Mesothelioma
M. Onda (2006)
10.1016/J.JSS.2004.03.028
The role of Osteopontin in tumor metastasis.
P. Wai (2004)
10.1038/sj.bjc.6601839
Role of osteopontin in tumour progression
S. R. Rittling (2004)
10.1016/0169-5002(95)00595-1
Osteopontin expression in lung cancer.
A. Chambers (1996)
10.1046/j.1365-2559.1997.5460776.x
Pathology of malignant mesothelioma
R. Attanoos (1997)
10.4161/cbt.4.7.1821
Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions
A. Kolb (2005)
10.1073/PNAS.93.1.136
Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.
K. Chang (1996)
10.1038/sj.bjc.6602715
Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer
L. Boldrini (2005)
Cutpoint determination methods in survival analysis using SASR
Mandrekar Mandrekarjn
10.1111/j.1349-7006.2006.00246.x
Novel ELISA system for detection of N‐ERC/mesothelin in the sera of mesothelioma patients
K. Shiomi (2006)
Osteopontin expression and distribution in human carcinomas.
L. F. Brown (1994)
10.1073/PNAS.96.20.11531
Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma.
N. Scholler (1999)
Osteo - pontin expression and prognostic significance in non - small cell lung cancer
DonatiV (2005)
Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer.
N. Fedarko (2001)
American Association for Cancer clincancerres.aacrjournals.org Downloaded from
(2007)
10.1159/000086961
Clinical Significance of Osteopontin in Esophageal Squamous Cell Carcinoma: Comparison with Common Tumor Markers
Y. Shimada (2005)
10.1164/RCCM.200209-1113OC
High plasma osteopontin level and its relationship with interleukin-12-mediated type 1 T helper cell response in tuberculosis.
Y. Koguchi (2003)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1158/1055-9965.EPI-06-0479
Mesothelin Is Shed from Tumor Cells
M. Ho (2006)
10.4161/cbt.4.12.2166
Expression of osteopontin and HGF/Met in adult soft tissue tumors
V. Bramwell (2005)
secrete specific proteins and phospho - proteins
K Chang (1979)
10.1056/nejmoa051185
Asbestos exposure, pleural mesothelioma, and serum osteopontin levels.
H. Pass (2005)
10.2307/2530051
Analysis of covariance using the rank transformation.
W. J. Conover (1982)
10.1158/1078-0432.CCR-04-2013
Overexpression of Osteopontin Is Associated with More Aggressive Phenotypes in Human Non–Small Cell Lung Cancer
Z. Hu (2005)
Mesothelinfamily proteins and diagnosis ofmesothelioma
BW Robinson (2003)
10.1097/00000478-200311000-00003
Application of Mesothelin Immunostaining in Tumor Diagnosis
N. Ordóñez (2003)
10.1016/S0140-6736(03)14794-0
Mesothelin-family proteins and diagnosis of mesothelioma
B. Robinson (2003)
10.1016/S0167-9473(98)00096-6
An application of changepoint methods in studying the effect of age on survival in breast cancer
C. Contal (1999)
10.1016/0169-5002(94)92126-1
Pathology of malignant mesothelioma.
E. V. Van marck (2004)
Transformedmam - malian
DR Senger (2004)
10.1007/978-3-642-10862-4
[Malignant mesothelioma].
J. Espinosa Arranz (1994)
Detection and quantitation of serum mesothelin , a tumor marker for patients with mesothelioma and ovarian cancer
R Hassan (2006)
10.1158/1078-0432.CCR-05-1477
Detection and Quantitation of Serum Mesothelin, a Tumor Marker for Patients with Mesothelioma and Ovarian Cancer
R. Hassan (2006)
10.1016/0009-9120(96)84728-A
Quantification of osteopontin in human plasma with an ELISA: basal levels in pre- and postmenopausal women.
D. Bautista (1996)
Osteo - pontin expression in
AF Chambers (1994)
10.1158/1078-0432.CCR-05-0541
Osteopontin Expression and Prognostic Significance in Non–Small Cell Lung Cancer
V. Donati (2005)



This paper is referenced by
10.21037/tlcr.2017.05.06
Diagnostic and prognostic biomarkers for malignant mesothelioma: an update.
Z. Chen (2017)
10.1164/rccm.200802-258OC
Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study.
E. Park (2008)
10.1158/1078-0432.CCR-10-1929
Serum Soluble Mesothelin Concentrations in Malignant Pleural Mesothelioma: Relationship to Tumor Volume, Clinical Stage and Changes in Tumor Burden
J. Creaney (2010)
10.1038/bjc.2014.478
Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales
A. Linton (2014)
Mechanisms of TRAIL resistance
N. Kumar (2018)
Pairon Cancers respiratoires professionnels
J. Pairon (2008)
- 1-Comparisons and combinations of the five tumor markers for mesothelioma : NERC / mesothelin , osteopontin , hyaluronic acid , CA 125 , and CYFRA 21-1
K. Shiomi (2011)
10.1183/09031936.00063109
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)
10.5507/bp.2014.014
Prevalence and clinical significance of liver function abnormalities in patients with acute heart failure.
K. Vyskočilová (2015)
10.1007/978-3-319-40618-3_37
Malignant pleural mesothelioma.
D. Ettinger (2012)
10.1164/rccm.200907-1020OC
Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.
K. Hollevoet (2010)
10.1016/j.lungcan.2013.09.017
The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma.
Takayuki Muraoka (2013)
10.1111/j.1440-1843.2010.01890.x
Translational advances in pleural malignancies
Georgios T. Stathopoulos (2011)
10.1200/JCO.2011.39.6671
Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.
Kevin Hollevoet (2012)
10.5772/intechopen.89438
Asbestos-Related Diseases and Blood Biomarkers
A. Franko (2019)
10.1016/S1877-1203(09)72518-2
Diagnostic et bilan du mésothéliome pleural malin
X. Dhalluin (2009)
10.1016/j.clinbiochem.2009.03.007
Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma.
B. Grigoriu (2009)
10.1016/j.mrrev.2011.12.003
A review of transcriptome studies combined with data mining reveals novel potential markers of malignant pleural mesothelioma.
O. Melaiu (2012)
10.1515/cclm-2012-0314
A predictive equation to adjust for clinical variables in soluble mesothelin-related protein (SMRP) levels
E. Park (2012)
10.1016/j.humpath.2015.02.006
Prognostic factors in malignant pleural mesothelioma.
B. Davidson (2015)
10.1177/0004563217741145
Biomarkers in mesothelioma
D. Arnold (2018)
10.1016/j.jtcvs.2011.04.034
Detection of integrin-linked kinase in the serum of patients with malignant pleural mesothelioma.
S. Watzka (2011)
10.1016/S0761-8425(08)71517-1
Cancers respiratoires professionnels
J. Pairon (2008)
10.1111/1759-7714.12967
Characteristics and long‐term outcomes of advanced pleural mesothelioma in Latin America (MeSO‐CLICaP)
L. Rojas (2019)
Malignant pleural mesothelioma : novel biomarkers and related pathways
Filip Mundt (2013)
Clinical Significance of SerumMesothelin in Patients with Mesothelioma and Lung Cancer
Alfonso Cristaudo (2007)
10.1158/1078-0432.CCR-08-0360
Osteopontin Levels in an Asbestos-Exposed Population
E. Park (2009)
10.21037/atm.2017.06.60
Diagnosis and prognosis-review of biomarkers for mesothelioma.
H. H. Sun (2017)
10.1371/journal.pone.0072030
Hyaluronan and N-ERC/Mesothelin as Key Biomarkers in a Specific Two-Step Model to Predict Pleural Malignant Mesothelioma
Filip Mundt (2013)
10.21873/cgp.20183
Putative Biomarkers for Malignant Pleural Mesothelioma Suggested by Proteomic Analysis of Cell Secretome
Serena Lacerenza (2020)
10.1016/S1877-1203(09)72544-3
Atteinte maligne de la plèvre
Xavier Dhalluin (2009)
10.5455/JEOS.20141223050627
Asbestos and its substitutes: International coordination and independent research needed -
S. Jargin (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar